Find a Clinical Trial
See the list of featured NIAID clinical trials below or view the complete list of NIAID studies recruiting participants on ClinicalTrials.gov.
The trial primarily is designed to determine if the vaccine candidate, AZD1222, can prevent symptomatic COVID-19 after two doses.
The primary purpose of the ACTIV-5/BET study is to evaluate the clinical efficacy of different investigational therapeutics in adults hospitalized for severe COVID-19.
Cardiopulmonary Inflammation and Multi-System Imaging During COVID-19 Infection in Asymptomatic and Symptomatic Persons
A study to learn how coronavirus affects different organs of the body and the function of the body's immune system.
COVID-19 Antibody Treatment Study for Preventing SARS-CoV-2 Infection in Nursing Home Residents and Staff
This trial will assess whether LY-CoV555, a potential COVID-19 antibody treatment, can prevent SARS-CoV-2 infection among people at high risk of exposure due to residing or working in skilled nursing or assisted living facilities.
The NIAID Vaccine Research Center is looking for volunteers who are fully recovered from confirmed COVID-19 infection to donate blood for a research study. The aim of the study is to further define and understand specific immune responses.
This study looks at the safety and effectiveness of different drugs in treating COVID-19 in outpatients. Participants in the study will receive an experimental therapy or a placebo.
This research study is about an experimental drug for COVID-19 called NT-I7. We are studying whether the experimental drug is safe for people with COVID-19. We also want to see if it might help treat COVID-19 by supporting the immune system.
The goal of this study is to learn more about the genetic contributions to the severity of disease in COVID-19. We hope to use this information to develop therapies to reduce the severity of symptoms of COVID-19 in some people.
An NIAID-supported study being conducted at 10 research sites across the United States will track the immune responses of people hospitalized with COVID-19.
This protocol will serve as a platform for assessing treatments for adult patients hospitalized for medical management of COVID-19 without related serious end-organ failure. Trials will involve sites around the world strategically chosen to ensure rapid enrollment. This trial will compare hyperimmune intravenous immunoglobulin (hIVIG) with matched placebo, when added to standard of care (SOC), for preventing further disease progression and mortality related to COVID-19. SOC will include remdesivir unless it is contraindicated for an individual patient.
Monoclonal Antibodies Study for Prevention of SARS CoV-2 Infection in Healthy Adults Who Are Household Contacts to an Individual With a Positive COVID-19 Test
This study will evaluate Regeneron’s investigational double monoclonal antibody (mAb) combination, REGN-COV-2, which is designed to bind to two points on the SARS-CoV-2 spike protein and prevent it from entering healthy cells.
A study at the NIH Clinical Center in Bethesda, Maryland aims to determine how many adults in the United States without a confirmed history of infection with SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), have antibodies to the virus. The presence of antibodies in the blood indicates a prior infection. In this “serosurvey,” researchers will collect and analyze blood samples from as many as 10,000 volunteers to provide critical data for epidemiological models. The results will help illuminate the extent to which the novel coronavirus has spread undetected in the United States and provide insights into which communities and populations are most affected.
A study about how SARS-CoV-2, the virus that causes COVID-19, affects the body, specifically how it affects blood cells and the immune system.
A study about long-term medical problems experienced by people who recover from COVID-19 and whether people who recover develop long-term immunity to SARS-CoV-2, the virus that causes COVID-19.
The trial is designed to evaluate if the investigational Janssen COVID-19 vaccine (JNJ-78436725) can prevent symptomatic COVID-19 after a single dose.
The COVID-19 Prevention Network (CoVPN) is conducting studies to find safe and effective vaccines and monoclonal antibodies for (SARS-CoV-2), the virus that causes COVID-19.
The mRNA-1273 vaccine is being developed to prevent COVID-19. The purpose of this study is to test Moderna’s vaccine candidate to see if it can prevent illness if people are exposed to the SARS-CoV-2 virus in their everyday lives. The mRNA-1273 vaccine is not made from the SARS-CoV-2 virus.
Coronaviruses and Flu (Influenza)
Study of the Immune Response to the Seasonal Influenza Vaccine and How Previous Infection With SARS-CoV-2 May Change That Response
This study evaluates the response of the immune system, the part of the body that helps fight infections, to the seasonal influenza vaccine in healthy individuals and also investigates whether prior SARS-CoV-2 infection may change that response.